ERBB2 in Pediatric Cancer: Innocent Until Proven Guilty

ERBB2 in Pediatric Cancer: Innocent Until Proven Guilty Richard J. Gilbertson Oncologist 2005; 10: 508-517 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in pediatric oncology and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Review the key aspects of ERBB2 signal biology in normal and cancer cells. Outline available evidence for the involvement of ERBB2 signaling in different pediatric solid cancers. Describe the key challenges associated with translating molecular targeted therapies of adult cancers to pediatric patients. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Aug. 03, 2005 Most Recent Review: Aug. 03, 2005* Most Recent Update: Aug. 03, 2005 Date Credit Expires: Aug. 03, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.